Cargando…
Fixed-Dose Combination of NSAIDs and Spasmolytic Agents in the Treatment of Different Types of Pain—A Practical Review
This review presents the most common disease entities in which combinations of NSAIDs and spasmolytic drugs are used to reduce pain. The benefits of fixed-dose combination products (FDCs) are that they improve the response in people with insufficient monotherapy. Using the synergy or additive effect...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306558/ https://www.ncbi.nlm.nih.gov/pubmed/34300284 http://dx.doi.org/10.3390/jcm10143118 |
_version_ | 1783727839564005376 |
---|---|
author | Janczura, Magdalena Kobus-Moryson, Małgorzata Sip, Szymon Żarowski, Marcin Wareńczak, Agnieszka Cielecka-Piontek, Judyta |
author_facet | Janczura, Magdalena Kobus-Moryson, Małgorzata Sip, Szymon Żarowski, Marcin Wareńczak, Agnieszka Cielecka-Piontek, Judyta |
author_sort | Janczura, Magdalena |
collection | PubMed |
description | This review presents the most common disease entities in which combinations of NSAIDs and spasmolytic drugs are used to reduce pain. The benefits of fixed-dose combination products (FDCs) are that they improve the response in people with insufficient monotherapy. Using the synergy or additive effect of drugs, it is possible to obtain a significant therapeutic effect and faster action with the use of smaller doses of individual drugs. In addition, one active ingredient may counteract adverse reactions from the other. Another essential aspect of the use of FDCs is the improvement of medical adherence due to the reduction in the pill burden on patients. It is also possible to develop a fixed-dosed combination product de novo to address a new therapeutic claim and be protected by patents so that the manufacturer can obtain exclusive rights to sell a particular FDC or a formulation thereof. The proposed fixed-dose combinations should always be based on valid therapeutic principles and consider the combined safety profile of all active substances included in the medicinal product. This review aims to identify which combinations of NSAIDs and spasmolytics have been developed and tested and which combinations are still under development. |
format | Online Article Text |
id | pubmed-8306558 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83065582021-07-25 Fixed-Dose Combination of NSAIDs and Spasmolytic Agents in the Treatment of Different Types of Pain—A Practical Review Janczura, Magdalena Kobus-Moryson, Małgorzata Sip, Szymon Żarowski, Marcin Wareńczak, Agnieszka Cielecka-Piontek, Judyta J Clin Med Review This review presents the most common disease entities in which combinations of NSAIDs and spasmolytic drugs are used to reduce pain. The benefits of fixed-dose combination products (FDCs) are that they improve the response in people with insufficient monotherapy. Using the synergy or additive effect of drugs, it is possible to obtain a significant therapeutic effect and faster action with the use of smaller doses of individual drugs. In addition, one active ingredient may counteract adverse reactions from the other. Another essential aspect of the use of FDCs is the improvement of medical adherence due to the reduction in the pill burden on patients. It is also possible to develop a fixed-dosed combination product de novo to address a new therapeutic claim and be protected by patents so that the manufacturer can obtain exclusive rights to sell a particular FDC or a formulation thereof. The proposed fixed-dose combinations should always be based on valid therapeutic principles and consider the combined safety profile of all active substances included in the medicinal product. This review aims to identify which combinations of NSAIDs and spasmolytics have been developed and tested and which combinations are still under development. MDPI 2021-07-15 /pmc/articles/PMC8306558/ /pubmed/34300284 http://dx.doi.org/10.3390/jcm10143118 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Janczura, Magdalena Kobus-Moryson, Małgorzata Sip, Szymon Żarowski, Marcin Wareńczak, Agnieszka Cielecka-Piontek, Judyta Fixed-Dose Combination of NSAIDs and Spasmolytic Agents in the Treatment of Different Types of Pain—A Practical Review |
title | Fixed-Dose Combination of NSAIDs and Spasmolytic Agents in the Treatment of Different Types of Pain—A Practical Review |
title_full | Fixed-Dose Combination of NSAIDs and Spasmolytic Agents in the Treatment of Different Types of Pain—A Practical Review |
title_fullStr | Fixed-Dose Combination of NSAIDs and Spasmolytic Agents in the Treatment of Different Types of Pain—A Practical Review |
title_full_unstemmed | Fixed-Dose Combination of NSAIDs and Spasmolytic Agents in the Treatment of Different Types of Pain—A Practical Review |
title_short | Fixed-Dose Combination of NSAIDs and Spasmolytic Agents in the Treatment of Different Types of Pain—A Practical Review |
title_sort | fixed-dose combination of nsaids and spasmolytic agents in the treatment of different types of pain—a practical review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306558/ https://www.ncbi.nlm.nih.gov/pubmed/34300284 http://dx.doi.org/10.3390/jcm10143118 |
work_keys_str_mv | AT janczuramagdalena fixeddosecombinationofnsaidsandspasmolyticagentsinthetreatmentofdifferenttypesofpainapracticalreview AT kobusmorysonmałgorzata fixeddosecombinationofnsaidsandspasmolyticagentsinthetreatmentofdifferenttypesofpainapracticalreview AT sipszymon fixeddosecombinationofnsaidsandspasmolyticagentsinthetreatmentofdifferenttypesofpainapracticalreview AT zarowskimarcin fixeddosecombinationofnsaidsandspasmolyticagentsinthetreatmentofdifferenttypesofpainapracticalreview AT warenczakagnieszka fixeddosecombinationofnsaidsandspasmolyticagentsinthetreatmentofdifferenttypesofpainapracticalreview AT cieleckapiontekjudyta fixeddosecombinationofnsaidsandspasmolyticagentsinthetreatmentofdifferenttypesofpainapracticalreview |